HIGHLIGHTS
- who: Thibault Dupont from the (UNIVERSITY) have published the research: Etoposide treatment in secondary hemophagocytic syndrome: impact on healthcare-associated infections and survival, in the Journal: (JOURNAL)
- what: The aim of this study was to assess the influence of etoposide administration on the rate of HAIs in critically ill patients with sHS, and to evaluate whether etoposide is associated with mortality. This study has been approved by the Ethics Committee of the French Intensive Care Society (FICS, no. CE-21-20). The authors focused on patients with any microbiologically documented infection diagnosed after ICU admission . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.